PHI vs COGT Comparison

PLDT Inc is a telecommunications and digital services provider. The group has three reportable operating segments: Wireless, Fixed Line, and Others. Maximum revenue is generated from its Fixed Line segment, which offers fixed line telecommunications services, servicing retail, corporate, and small and medium-sized enterprises clients. The Fixed Line business segment offers data, voice, and miscellaneous services. It also offers secure data centers, multi-cloud, cybersecurity, data, and artificial intelligence (AI) solutions through different subsidiaries. The Wireless segment generates revenue by offering access to mobile internet via smartphones, mobile broadband using pocket WiFi, or home WiFi using fixed wireless broadband devices. Geographically, the group operates in the Philippines.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.